Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation

Blood

Volumn 117, Issue 18, 2011, Pages 4759-4768

  Jo, Stephanie Y ^a   Granowicz, Eric M ^a   Maillard, Ivan ^a,b   Thomas, Dafydd ^a   Hess, Jay L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISRUPTOR OF TELOMERIC SILENCING 1 LIKE ENZYME; METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL CYCLE; GENE DELETION; GENE EXPRESSION; GENE LOSS; HEMATOPOIESIS; HOMEOSTASIS; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PANCYTOPENIA; PRIORITY JOURNAL;

EID: 79955948524     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-327668     Document Type: Article

References (39)

1. Singer M, Kahana A, Wolf A, et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics. 1998;150(2):613-632. (Pubitemid 28463040)
2. Min J, Feng Q, Li Z, Zhang Y, Xu R. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell. 2003;112(5):711-723. (Pubitemid 36331782)
3. Feng Q, Wang H, Ng H, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol. 2002;12(12):1052-1058. (Pubitemid 34703339)
4. van Leeuwen F, Gafken P, Gottschling D. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell. 2002;109(6):745-756. (Pubitemid 34727348)
5. Ng H, Feng Q, Wang H, et al. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev. 2002;16(12):1518-1527. (Pubitemid 34686333)
6. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
7. Barry ER, Corry GN, Rasmussen TP. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opin Ther Targets. 2010;14(4):405-418.
8. Chang MJ, Wu H, Achille NJ, et al. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010;70(24):10234-10242.
9. Karlić R, Chung H, Lasserre J, Vlahovicek K, Vingron M. Histone modification levels are predictive for gene expression. Proc Natl Acad Sci U S A. 2010;107(7):2926-2931.
10. Steger D, Lefterova M, Ying L, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008;28(8):2825-2839. (Pubitemid 351542379)
11. Vakoc C, Sachdeva M, Wang H, Blobel G. Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol. 2006;26(24):9185-9195. (Pubitemid 44904415)
12. Barry E, Krueger W, Jakuba C, et al. ES cell cycle progression and differentiation require the action of the histone methyltransferase Dot1L. Stem Cells. 2009;27(7):1538-1547.
13. Jones B, Su H, Bhat A, et al. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 2008;4(9):e1000190.
14. Feng Y, Yang Y, Ortega MM, et al. Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood. 2010;116(22):4483-4491.
15. Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490-1499.
16. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110(13):4445-4454. (Pubitemid 351377811)
17. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121(2):167-178. (Pubitemid 40546386)
18. Bitoun E, Oliver P, Davies K. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet. 2007;16(1):92-106. (Pubitemid 46152547)
19. Monroe S, Jo S, Sanders D, et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol. 2011;39(1):77-86.
20. Mohan M, Herz HM, Takahashi YH, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24(6):574-589.
21. Benedikt A, Baltruschat S, Scholz B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 2011;25(1):135-144.
22. Bursen A, Schwabe K, Rüster B, et al. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood. 2010;115(17):3570-3579.
23. Krivtsov A, Feng Z, Lemieux M, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5):355-368.
24. Testa G, Schaft J, van der Hoeven F, et al. A reliable lacZ expression reporter cassette for multi-purpose, knockout-first alleles. Genesis. 2004;38(3):151-158. (Pubitemid 38506853)
25. Muntean AG, Giannola D, Udager AM, Hess JL. The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood. 2008;112(12):4690-4693.
26. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17(13):3714-3725. (Pubitemid 28327389)
27. Kiel M, Yilmaz O, Iwashita T, Terhorst C, Morrison S. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109-1121. (Pubitemid 40884400)
28. Maillard I, Chen Y, Friedman A, et al. Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood. 2009;113(8):1661-1669.
29. Pronk C, Rossi D, Månsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442. (Pubitemid 47506534)
30. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16(14):4226-4237. (Pubitemid 27298175)
31. Zeisig B, Milne T, García-Cuéllar M, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24(2):617-628. (Pubitemid 38057914)
32. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18):2298-2307. (Pubitemid 37128644)
33. Mueller D, García-Cuéllar M, Bach C, Buhl S, Maethner E, Slany R. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 2009;7(11):e1000249.
34. Hisa T, Spence SE, Rachel RA, et al. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J. 2004;23(2):450-459. (Pubitemid 38294509)
35. Lawrence HJ, Helgason CD, Sauvageau G, et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood. 1997;89(6):1922-1930. (Pubitemid 27132106)
36. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and 'oncogenic shock.' Biochem Pharmacol. 2010;80(5):666-673.
37. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899-902. (Pubitemid 41076430)
38. Bansal D, Scholl C, Fröhling S, et al. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci U S A. 2006;103(45):16924-16929. (Pubitemid 44737354)
39. Rawat VP, Thoene S, Naidu VM, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood. 2008;111(1):309-319.